Advisor Resource Council acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,800 shares of the biotechnology company’s stock, valued at approximately $336,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Camber Capital Management LP purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at about $88,884,000. Jennison Associates LLC bought a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $48,817,000. Fort Washington Investment Advisors Inc. OH boosted its position in shares of BioMarin Pharmaceutical by 93.2% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,143,631 shares of the biotechnology company’s stock valued at $101,040,000 after acquiring an additional 551,729 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of BioMarin Pharmaceutical by 116.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 791,789 shares of the biotechnology company’s stock valued at $61,197,000 after acquiring an additional 425,289 shares during the last quarter. Finally, Rockefeller Capital Management L.P. boosted its position in shares of BioMarin Pharmaceutical by 41.6% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 1,151,859 shares of the biotechnology company’s stock valued at $89,025,000 after acquiring an additional 338,406 shares during the last quarter. 95.45% of the stock is owned by institutional investors.
A number of analysts have recently issued reports on the company. Morgan Stanley upgraded BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $96.00 to $113.00 in a research report on Monday, April 25th. Stifel Nicolaus restated a “buy” rating and issued a $96.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 3rd. Wedbush dropped their target price on BioMarin Pharmaceutical from $155.00 to $147.00 in a research report on Thursday, April 28th. StockNews.com upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, Jefferies Financial Group restated a “buy” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, May 4th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $111.93.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last posted its earnings results on Wednesday, April 27th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.16. The firm had revenue of $519.36 million for the quarter, compared to analysts’ expectations of $505.11 million. BioMarin Pharmaceutical had a return on equity of 1.36% and a net margin of 2.09%. During the same period in the previous year, the firm earned $0.29 earnings per share. Research analysts forecast that BioMarin Pharmaceutical Inc. will post 0.94 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 15,000 shares of the business’s stock in a transaction on Thursday, March 10th. The stock was sold at an average price of $77.57, for a total value of $1,163,550.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brian Mueller sold 11,800 shares of the business’s stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $84.50, for a total value of $997,100.00. Following the completion of the sale, the chief financial officer now directly owns 38,639 shares in the company, valued at $3,264,995.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 131,727 shares of company stock worth $10,786,429. 1.75% of the stock is owned by insiders.
About BioMarin Pharmaceutical (Get Rating)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.